性别中立人乳头瘤病毒疫苗接种建议的景观评估:纳入头颈癌负担数据
该研究通过系统文献综述评估各国机构在评价HPV性别中立疫苗接种(GNV)项目时是否纳入HPV相关头颈癌(HNC)数据。结果显示多数报告考虑口咽癌且认为男性发病率与死亡率更高,多个报告结论GNV项目相比不接种男性可能具有成本效果。
要点
- 多数国家评估在讨论HNC时考虑口咽癌,且一致认为男性口咽癌发病率更高。
- 多个报告结论HPV性别中立疫苗接种项目相比不接种男性可能具有成本效果。
- 部分国家因数据有限可能低估了HPV相关HNC的流行病学负担。
核心结论
- 多个HTA机构与NITAG在评价HPV性别中立疫苗接种项目时已认识到普通男性人群中HPV相关HNC的负担。
- 已识别的GNV项目评估强烈提示具有成本效果的临床获益。
- 部分国家因数据有限可能低估了HNC的流行病学负担,需进一步研究获取更稳健数据。
研究设计与样本
- 系统文献综述,检索MEDLINE与EMBASE数据库及选定国家机构网站。
主要发现
- 2018年全球HNC超过450,000例死亡和900,000例病例,其中38,000例归因于HPV。
- HNC在男性中的患病率是女性的两至四倍。
- 近年HPV引起的口咽癌和口腔癌发病率上升。
- 所有考虑发病率数据的报告一致认为男性口咽癌发病率更高,且HPV相关HNC死亡率在男性中也更高。
关键数值与推荐
- 评估中的增量成本效果比(ICER)差异很大,因分析输入异质性大。
- 多个报告结论GNV项目相比不接种男性可能具有成本效果。
临床怎么用
- 在评估HPV性别中立疫苗接种项目时,应纳入HPV相关HNC(尤其是口咽癌)的流行病学与经济负担数据。
- 男性HPV相关HNC的发病率与死亡率更高,支持将男性纳入HPV疫苗接种策略的考虑。
局限性
- 部分国家因数据有限可能低估了HNC的流行病学负担。
- 各评估的经济学输入异质性大,导致ICER差异广泛。
- 需进一步研究获取更稳健数据以弥补男性HPV相关HNC流行病学与经济负担的信息缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Head and neck cancers (HNC) accounted for over 450,000 deaths and 900,000 cases in 2018 worldwide. Of those, 38,000 cases were attributable to human papillomavirus (HPV). HNC is two to four times more prevalent in men than in women. The incidence of oropharyngeal cancers (OPC) and oral cavity cancers caused by HPV has increased in recent decades. Given the substantial burden of HPV-related HNC in males, this study aimed to assess whether and how national agencies included HPV-related HNC when evaluating HPV genderneutral vaccination (GNV) programs. METHODS: A systematic literature review was conducted in MEDLINE® and EMBASE®, and on the websites of selected national agencies. RESULTS: Searches identified a potential 205 records; seventeen were eligible for the review. Seventy percent of assessments were published by European countries and most were recent (2014-2019). Eleven (65%) reports considered OPC when discussing HNC, and a few included other anatomic sites. All reports that considered incidence data were in consensus that incidence of OPC was higher in men and showed that the mortality rates for HPV-related HNC were also higher in men. When looking at the economic impact, the incremental cost-effectiveness ratios in the assessments varied widely, as the inputs into the analyses were heterogeneous. However, several reports concluded GNV programs were likely to be cost-effective versus not vaccinating males. CONCLUSION: The burden of HPV-related HNC in the general male population has been recognized by several Heatlth Technology Assessment (HTA) agencies and National Immunization Technical Advisory Groups (NITAGs) when evaluating HPV GNV programs. The assessments identified on GNV programs strongly indicate a cost-effective clinical benefit. Nevertheless, the epidemiological burden of HNC may have been underestimated in some countries due to limited data. Further research is crucial to obtain more robust data that will help address the information gap in epidemiological and economic burden of HPV-associated HNC in men.
引用
- Morais E, El Mouaddin N, Schuurman S, et al. Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data. Vaccine. 2021. PMID: 34452775. doi:10.1016/j.vaccine.2021.08.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。